Montis: Exploring an untouched macrophage subset in immuno-oncology

Montis is targeting the tumor vasculature to boost antitumor immunity

Montis launched with €8.4 million and a concept that puts an immuno-oncology spin on the tumor vasculature, marking the second company seeded by oncology-focused Droia Ventures in as many weeks.

Droia, which teamed up with the Flanders Institute for Biotechnology (VIB) and Catholic University Leuven (KU Leuven) to found the company, was joined by

Read the full 548 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE